Top

Cancer Causes & Control

Published in:

Open Access 01-08-2013 | Original paper

Risk of mesothelioma following external beam radiotherapy for prostate cancer: a cohort analysis of SEER database

Authors: Andrea Farioli, Francesco Saverio Violante, Stefano Mattioli, Stefania Curti, David Kriebel

Published in: Cancer Causes & Control | Issue 8/2013

Abstract

Purpose

To investigate the association between external beam radiotherapy (EBRT) for prostate cancer and mesothelioma using data from the US Surveillance, Epidemiology, and End Results (SEER) cancer registries.

Methods

We analyzed data from the SEER database (1973–2009). We compared EBRT versus no radiotherapy. Incidence rate ratios (IRR) and 95 % confidence intervals (95 % CI) of mesothelioma among prostate cancer patients were estimated with multilevel Poisson models adjusted by race, age, and calendar year. Confounding by asbestos was investigated using relative risk of mesothelioma in each case’s county of residence as a proxy for asbestos exposure.

Results

Four hundred and seventy-one mesothelioma cases (93.6 % pleural) occurred in 3,985,991 person-years. The IRR of mesothelioma was increased for subjects exposed to EBRT (1.28; 95 % CI 1.05, 1.55) compared to non-irradiated patients, and a population attributable fraction of 0.49 % (95 % CI 0.11, 0.81) was estimated. The IRR increased with latency period: 0–4 years, IRR 1.08 (95 % CI 0.81, 1.44); 5–9 years, IRR 1.31 (95 % CI 0.93, 1.85); ≥10 years, IRR 1.59 (95 % CI 1.05, 2.42). Despite the fairly strong evidence of association with EBRT, the population attributable rate of mesothelioma was modest—3.3 cases per 100,000 person-years. The cumulative incidence of mesothelioma attributable to EBRT was 4.0/100,000 over 5 years, 24.5/100,000 over 10 years, and 65.0/100,000 over 15 years.

Conclusions

Our study provides evidence that EBRT for prostate cancer is a small but detectable risk factor for mesothelioma. Patients should be advised of risk of radiation-induced second malignancies.

Available only for authorised users

Price B, Ware A (2004) Mesothelioma trends in the United States: an update based on surveillance, epidemiology, and end results program data for 1973 through 2003. Am J Epidemiol 159:107–112. doi:10.1093/aje/kwh025 PubMedCrossRef

Moore AJ, Parker RJ, Wiggins J (2008) Malignant mesothelioma. Orphanet J Rare Dis 3:34. doi:10.1186/1750-1172-3-34 PubMedCrossRef

Goldberg M, Imbernon E, Rolland P, Gilg Soit Ilg A, Savès M, de Quillacq A, Frenay C, Chamming’s S, Arveux P, Boutin C, Launoy G, Pairon JC, Astoul P, Galateau-Sallé F, Brochard P (2006) The French national mesothelioma surveillance program. Occup Environ Med 63:390–395. doi:10.1136/oem.2005.023200 PubMedCrossRef

Rake C, Gilham C, Hatch J, Darnton A, Hodgson J, Peto J (2009) Occupational, domestic and environmental mesothelioma risks in the British population: a case-control study. Br J Cancer 100:1175–1183. doi:10.1038/sj.bjc.6604879 PubMedCrossRef

Rushton L, Bagga S, Bevan R, Brown TP, Cherrie JW, Holmes P, Fortunato L, Slack R, Van Tongeren M, Young C, Hutchings SJ (2010) Occupation and cancer in Britain. Br J Cancer 102:1428–1437. doi:10.1038/sj.bjc.6605637 PubMedCrossRef

Driscoll T, Nelson DI, Steenland K, Leigh J, Concha-Barrientos M, Fingerhut M, Prüss-Ustün A (2005) The global burden of disease due to occupational carcinogens. Am J Ind Med 48:419–431. doi:10.1002/ajim.20209 PubMedCrossRef

Moolgavkar SH, Meza R, Turim J (2009) Pleural and peritoneal mesotheliomas in SEER: age effects and temporal trends, 1973–2005. Cancer Causes Control 20:935–944. doi:10.1007/s10552-009-9328-9 PubMedCrossRef

Jasani B, Gibbs A (2012) Mesothelioma not associated with asbestos exposure. Arch Pathol Lab Med 136:262–267. doi:10.5858/arpa.2011-0039-RA PubMedCrossRef

Goodman JE, Nascarella MA, Valberg PA (2009) Ionizing radiation: a risk factor for mesothelioma. Cancer Causes Control 20:1237–1254. doi:10.1007/s10552-009-9357-4 PubMedCrossRef

10.

Siegel R, Naishadham D, Jemal A (2012) Cancer statistics, 2012. CA Cancer J Clin 62:10–29. doi:10.3322/caac.20138 PubMedCrossRef

11.

Damber JE, Aus G (2008) Prostate cancer. Lancet 2008(371):1710–1721. doi:10.1016/S0140-6736(08)60729-1 CrossRef

12.

Bhojani N, Capitanio U, Suardi N, Jeldres C, Isbarn H, Shariat SF, Graefen M, Arjane P, Duclos A, Lattouf JB, Saad F, Valiquette L, Montorsi F, Perrotte P, Karakiewicz PI (2010) The rate of secondary malignancies after radical prostatectomy versus external beam radiation therapy for localized prostate cancer: a population-based study on 17,845 patients. Int J Radiat Oncol Biol Phys 76:342–348. doi:10.1016/j.ijrobp.2009.02.011 PubMedCrossRef

13.

Moon K, Stukenborg GJ, Keim J, Theodorescu D (2006) Cancer incidence after localized therapy for prostate cancer. Cancer 107:991–998. doi:10.1002/cncr.22083 PubMedCrossRef

14.

Brenner DJ, Curtis RE, Hall EJ, Ron E (2000) Second malignancies in prostate carcinoma patients after radiotherapy compared with surgery. Cancer 88:398–406. doi:10.1002/(SICI)1097-0142 PubMedCrossRef

15.

Enterline PE, Henderson VL (1987) Geographic patterns for pleural mesothelioma deaths in the United States, 1968–81. J Natl Cancer Inst 79:31–37. doi:10.1093/jnci/79.1.31 PubMed

16.

Fazzo L, De Santis M, Minelli G, Bruno C, Zona A, Marinaccio A, Conti S, Comba P (2012) Pleural mesothelioma mortality and asbestos exposure mapping in Italy. Am J Ind Med 55:11–24. doi:10.1002/ajim.21015 PubMedCrossRef

17.

Berrington de Gonzalez A, Curtis RE, Kry SF, Gilbert E, Lamart S, Berg CD, Stovall M, Ron E (2011) Proportion of second cancers attributable to radiotherapy treatment in adults: a cohort study in the US SEER cancer registries. Lancet Oncol 12:353–360. doi:10.1016/S1470-2045(11)70061-4 PubMedCrossRef

18.

Preston DL, Ron E, Tokuoka S, Funamoto S, Nishi N, Soda M, Mabuchi K, Kodama K (2007) Solid cancer incidence in atomic bomb survivors: 1958–1998. Radiat Res 168:1–64. doi:10.1667/RR0763.1 PubMedCrossRef

19.

Porta M (2008) A dictionary of epidemiology. Oxford University Press, New York

20.

Rabe-Hesketh S, Skrondal A (2008) Multilevel and longitudinal modeling using stata. Stata Press, College Station

21.

Besag J, York J, Mollie A (1991) Bayesian image restoration, with two applications in spatial statistics (with discussion). Ann Inst Stat Math 43:1–59. doi:10.1007 CrossRef

22.

Xu Y, Cheung YB, Lam KF, Tan SH, Milligan P (2010) A simple approach to the estimation of incidence rate difference. Am J Epidemiol 172:334–343. doi:10.1093/aje/kwq099 PubMedCrossRef

23.

Kry SF, Salehpour M, Followill DS, Stovall M, Kuban DA, White RA, Rosen II (2005) Out-of-field photon and neutron dose equivalents from step-and-shoot intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 62:1204–1216. doi:10.1016/j.ijrobp.2004.12.091 PubMedCrossRef

24.

Wax DB, Leibowitz AB (2007) Radiologic assessment of potential sites for needle decompression of a tension pneumothorax. Anesth Analg 105:1385–1388. doi:10.1213/01.ane.0000282827.86345.ff PubMedCrossRef

25.

Baxter NN, Tepper JE, Durham SB, Rothenberger DA, Virnig BA (2005) Increased risk of rectal cancer after prostate radiation: a population-based study. Gastroenterology 128:819–824. doi:10.1053/j.gastro.2004.12.038 PubMedCrossRef

26.

Francois P, Beurtheret C, Dutreix A (1988) Calculation of the dose delivered to organs outside the radiation beams. Med Phys 15:879–883. doi:10.1118/1.596170 PubMedCrossRef

27.

Hall EJ, Wuu CS (2003) Radiation-induced second cancers: the impact of 3D-CRT and IMRT. Int J Radiat Oncol Biol Phys 56:83–88. doi:10.1016/S0360-3016(03)00073-7 PubMedCrossRef

28.

Duchesne GM (2001) Radiation for prostate cancer. Lancet Oncol 2:73–81. doi:10.1016/S1470-2045(00)00223-0 PubMedCrossRef

29.

Mettler FA Jr, Huda W, Yoshizumi TT, Mahesh M (2008) Effective doses in radiology and diagnostic nuclear medicine: a catalog. Radiology 248:254–263. doi:10.1148/radiol.2481071451 PubMedCrossRef

30.

Berrington de González A, Darby S (2004) Risk of cancer from diagnostic X-rays: estimates for the UK and 14 other countries. Lancet 31(363):345–351. doi:10.1016/S0140-6736(04)15433-0 CrossRef

31.

Berrington de Gonzalez A, Curtis RE, Gilbert E, Berg CD, Smith SA, Stovall M, Ron E (2010) Second solid cancers after radiotherapy for breast cancer in SEER cancer registries. Br J Cancer 102:220–226. doi:10.1038/sj.bjc.6605435 PubMedCrossRef

32.

Robinson BW, Musk AW, Lake RA (2005) Malignant mesothelioma. Lancet 366:397–408. doi:10.1016/S0140-6736(05)67025-0 PubMedCrossRef

33.

Metz-Flamant C, Guseva Canu I, Laurier D (2011) Malignant pleural mesothelioma risk among nuclear workers: a review. J Radiol Prot 31:9–23. doi:10.1088/0952-4746/31/1/R01 PubMedCrossRef

34.

Hawkins NM, Jhund PS, McMurray JJ, Capewell S (2012) Heart failure and socioeconomic status: accumulating evidence of inequality. Eur J Heart Fail 14:138–146. doi:10.1093/eurjhf/hfr168 PubMedCrossRef

35.

Gershon AS, Dolmage TE, Stephenson A, Jackson B (2012) Chronic obstructive pulmonary disease and socioeconomic status: a systematic review. COPD 9:216–226. doi:10.3109/15412555.2011.648030 PubMedCrossRef

36.

Currie GP, Watt SJ, Maskell NA (2009) An overview of how asbestos exposure affects the lung. BMJ 24(339):b3209. doi:10.1136/bmj.b3209 CrossRef

37.

Hall WH, Jani AB, Ryu JK, Narayan S, Vijayakumar S (2005) The impact of age and comorbidity on survival outcomes and treatment patterns in prostate cancer. Prostate Cancer Prostatic Dis 8:22–30. doi:10.1038/sj.pcan.4500772 PubMedCrossRef

38.

Abdollah F, Sun M, Schmitges J, Thuret R, Tian Z, Shariat SF, Briganti A, Jeldres C, Perrotte P, Montorsi F, Karakiewicz PI (2012) Competing-risks mortality after radiotherapy vs. observation for localized prostate cancer: a population-based study. Int J Radiat Oncol Biol Phys 84:95–103. doi:10.1016/j.ijrobp.2011.11.034 PubMedCrossRef

39.

Cooperberg MR, Lubeck DP, Meng MV, Mehta SS, Carroll PR (2004) The changing face of low-risk prostate cancer: trends in clinical presentation and primary management. J Clin Oncol 22:2141–2149. doi:10.1200/JCO.2004.10.062 PubMedCrossRef

40.

Lyratzopoulos G, Barbiere JM, Greenberg DC, Wright KA, Neal DE (2010) Population based time trends and socioeconomic variation in use of radiotherapy and radical surgery for prostate cancer in a UK region: continuous survey. BMJ 340:1928. doi:10.1136/bmj.c1928 CrossRef

41.

McVey GP, McPhail S, Fowler S, McIntosh G, Gillatt D, Parker CC (2010) Initial management of low-risk localized prostate cancer in the UK: analysis of the British Association of Urological Surgeons Cancer Registry. BJU Int 106:1161–1164. doi:10.1111/j.1464-410X.2010.09288.x PubMedCrossRef

42.

Schymura MJ, Kahn AR, German RR, Hsieh MC, Cress RD, Finch JL, Fulton JP, Shen T, Stuckart E (2010) Factors associated with initial treatment and survival for clinically localized prostate cancer: results from the CDC-NPCR Patterns of Care Study (PoC1). BMC Cancer 10:152. doi:10.1186/1471-2407-10-152 PubMedCrossRef

43.

Dahabreh IJ, Chung M, Balk EM, Yu WW, Mathew P, Lau J, Ip S (2012) Active surveillance in men with localized prostate cancer: a systematic review. Ann Intern Med 17(156):582–590. doi:10.1059/0003-4819-156-8-201204170-00397 CrossRef

44.

Fraumeni JF Jr, Curtis RE, Edwards BK, Tucker MA (2006) Introduction. In: Curtis RE, Freedman DM, Ron E et al (eds) New malignancies among cancer survivors: SEER cancer registries, 1973–2000. National Cancer Institute, Bethesda, pp 1–7

45.

Husain AN, Colby T, Ordonez N, Krausz T, Attanoos R, Beasley MB, Borczuk AC, Butnor K, Cagle PT, Chirieac LR, Churg A, Dacic S, Fraire A, Galateau-Salle F, Gibbs A, Gown A, Hammar S, Litzky L, Marchevsky AM, Nicholson A, Roggli V, Travis WD, Wick M (2012) Guidelines for pathologic diagnosis of malignant mesothelioma: 2012 Update of the consensus statement from the international mesothelioma interest group. Arch Pathol Lab Med. doi:10.5858/arpa.2012-0214-OA

46.

Brenner DJ, Hall EJ, Curtis RE, Ron E (2005) Prostate radiotherapy is associated with second cancers in many organs, not just the colorectum. Gastroenterology 129:773–774. doi:10.1016/j.gastro.2005.06.045 PubMed

Title: Risk of mesothelioma following external beam radiotherapy for prostate cancer: a cohort analysis of SEER database
Authors: Andrea Farioli
Francesco Saverio Violante
Stefano Mattioli
Stefania Curti
David Kriebel
Publication date: 01-08-2013
Publisher: Springer Netherlands
Published in: Cancer Causes & Control / Issue 8/2013
Print ISSN: 0957-5243
Electronic ISSN: 1573-7225
DOI: https://doi.org/10.1007/s10552-013-0230-0

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on sleep in brain health

Springer Medicine

Abstract

Purpose

Methods

Results

Conclusions

Please log in to get access to this content

Other articles of this Issue 8/2013

Hormone replacement therapy and risk of meningioma in women: a meta-analysis

Recommendations for a national agenda to substantially reduce cervical cancer

Common variants in genes coding for chemotherapy metabolizing enzymes, transporters, and targets: a case–control study of contralateral breast cancer risk in the WECARE Study

Rural–urban differences in health behaviors and implications for health status among US cancer survivors

Synchronous and metachronous malignancies: analysis of the Minneapolis Veterans Affairs (VA) tumor registry

Associations among family history of cancer, cancer screening and lifestyle behaviors: a population-based study

Keynote webinar | Spotlight on antibody–drug conjugates in cancer